Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 9

1.
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.

Mental health policy and psychotropic drugs.

Frank RG, Conti RM, Goldman HH.

Milbank Q. 2005;83(2):271-98. Review.

4.

Pharmaceutical policies: effects of restrictions on reimbursement.

Green CJ, Maclure M, Fortin PM, Ramsay CR, Aaserud M, Bardal S.

Cochrane Database Syst Rev. 2010 Aug 4;(8):CD008654. doi: 10.1002/14651858.CD008654. Review.

PMID:
20687098
5.

Geographic variations in use of Medicaid mental health services.

Golberstein E, Rhee TG, McGuire TG.

Psychiatr Serv. 2015 May 1;66(5):452-4. doi: 10.1176/appi.ps.201400337. Epub 2015 Mar 1. Review.

PMID:
25726983
6.

Access and cost implications of state limitations on Medicaid reimbursement for pharmaceuticals.

Schweitzer SO, Shiota SR.

Annu Rev Public Health. 1992;13:399-410. Review. No abstract available.

PMID:
1599596
7.

Consumer/patient encounters with prescription drug monitoring programs: evidence from a Medicaid population.

Goodin A, Blumenschein K, Freeman PR, Talbert J.

Pain Physician. 2012 Jul;15(3 Suppl):ES169-75. Review.

8.

Assessing the present state and potential of Medicaid controlled substance lock-in programs.

Roberts AW, Skinner AC.

J Manag Care Spec Pharm. 2014 May;20(5):439-46c. Review.

9.

A survey of psychotropic medications not available in the United States.

Vinar O, Klein DF, Potter WZ, Gause EM.

Neuropsychopharmacology. 1991 Dec;5(4):201-17. Review.

PMID:
1804161
Items per page

Supplemental Content

Write to the Help Desk